NCT02516696 · REGISTRY CONDITION SEARCH

BiRd vs. Rd as Initial Therapy in Multiple Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE3
Status at capture: TERMINATED
Registry last update: 2023-06-05

This is a randomized, open-label, phase III study to investigate the efficacy of combination therapy with an induction phase utilizing a combination clarithromycin (Biaxin®), lenalidomide (Revlimid®), dexamethasone (Decadron®), in multiple myeloma patients who are newly diagnosed and require treatment when compared to patients who receive lenalidomide and dexamethasone alone.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Survival Duration Without Disease Progression

→

outcome · POSTED

Overall Response Rate

→

outcome · POSTED

Number of Adverse Events Experienced

→

outcome · POSTED

Overall Survival

→

outcome · POSTED

Number of Days After Initiating Treatment With BiRd Regimen to Disease Progression, as Compared to Subjects on Rd Treatment Regimen.

→

outcome · POSTED

Number of Patients With Objective Response Rate (CR+PR)

→

outcome · POSTED

Number of Patients With Complete Response Rate (CR)

→

outcome · POSTED

Number of Days for Event-Free Survival

→

outcome · POSTED

Number of Days for Duration of Response

→

outcome · POSTED

Number of Months to Progression-Free Survival 2

→

outcome · POSTED

Functional Assessment of Chronic Illness Therapy - Fatigue Subscale (FS; Version 4) Score of Patients Receiving BiRd vs Rd Treatment

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Subject must voluntarily sign and understand written informed consent. * Subject is at least 65 years old at the time of signing the consent form. * Subject has histologically confirmed multiple myeloma that has never before been treated * Subject has no prior anti-myeloma treatment therapy within 14 days prior to initiation of study treatment except for corticosteroids with a maximum allowed dosage equivalent to three pulses of dexamethasone (40mg daily for 4 days equals one pulse). Patients may have received prior adjuvant antiresorptive therapy (i.e., pamidronate or zoledronic acid) as routine care, or radiation therapy as palliation for pain and/or spinal cord compression. * Subject has measurable disease as defined by \> 0.5 g/dL serum monoclonal protein, \>10 mg/dL involved serum free light chain (either kappa or lambda) provided that the serum free light chain ratio is abnormal, \>0.2 g/24 hrs urinary M-protein excretion, and/or measurable plasmacytoma(s) of at least 1cm in greatest dimension as measured by either CT scanning or MRI. * Subject has a Karnofsky performance status ≥60% (\>50% if due to bony involvement of myeloma (see Appendix IV). * Subject is able to take prophylactic anticoagulation as detailed in section 9.1 (patients intolerant to aspirin may use warfarin or low molecular weight heparin). * Subject is registered into the mandatory RevAssist® program, and is willing and able to comply with the requirements of RevAssist® program. * If subject is a female of childbearing potential (FCBP),† she must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 - 14 days prior to and again within 24 hours of prescribing lenalidomide * Subject has a life expectancy ≥ 3 months * Subjects must meet the following laboratory parameters: * Absolute neutrophil count (ANC) ≥750 cells/mm3 (1.0 x 109/L) * Hemoglobin ≥ 7 g/dL * Platelet count ≥ 30,000/mm3 (75 x 109/L) * Serum SGOT/AST \<3.0 x upper limits of normal (ULN) * Serum SGPT/ALT \<3.0 x upper limits of normal (ULN) * Serum total bilirubin \<2.0 mg/dL (34 µmol/L) * Creatinine clearance ≥ 45 cc/min Exclusion Criteria: * Subject has immeasurable MM (no measurable monoclonal protein, free light chains in blood or urine, or measureable plasmacytoma on radiologic scanning). * Subject has a prior history of other malignancies unless disease free for ≥ 5 years, except for basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast, or localized prostate cancer with Gleason score \< 7 with stable prostate specific antigen (PSA) levels. * Subject has had myocardial infarction within 6 months prior to enrollment , or NYHA(New York Hospital Association) Class III or IV heart failure (see APPENDIX VI), Ejection Fraction \< 35%, uncontrolled angina, severe uncontrolled ventricular arrhythmias, electrocardiographic evidence of acute ischemia or active conduction system abnormalities. * Female subject who is pregnant or lactating. * Subject has known HIV infection * Subject has known active hepatitis B or hepatitis C infection. * Subject has active viral or bacterial infections or any coexisting medical problem that would significantly increase the risks of this treatment program. * Subject is unable to reliably take oral medications * Subject has known hypersensitivity to dexamethasone, clarithromycin, lenalidomide, or thalidomide * Subject has a history of thromboembolic event within the past 4 weeks prior to enrollment. * Subject has any clinically significant medical or psychiatric disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent. * Subject has previously been treated for multiple myeloma
healthy Volunteers: false
minimum Age: 65 Years
sex: ALL
std Ages: OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Subjects on the BiRD arm will receive clarithromycin, lenalidomide, and dexamethasone in 28-day cycles.
intervention Names
Drug: Clarithromycin
Drug: Lenalidomide
Drug: Dexamethasone
label
BiRD treatment regimen
type
EXPERIMENTAL
description
Subjects on the Rd arm will receive lenalidomide and dexamethasone in 28-day cycles.
intervention Names
Drug: Lenalidomide
Drug: Dexamethasone
label
Rd treatment regimen
type
ACTIVE_COMPARATOR

interventions

arm Group Labels
BiRD treatment regimen
description
500mg PO twice daily on days 1-28 for a 28-day cycle.
name
Clarithromycin
other Names
biaxin
type
DRUG
arm Group Labels
BiRD treatment regimen
Rd treatment regimen
description
25 mg PO days 1-21 followed by a 7 day rest period for each 28-day cycle
name
Lenalidomide
other Names
Revlimid
type
DRUG
arm Group Labels
BiRD treatment regimen
Rd treatment regimen
description
20 mg PO on Days 1, 8, 15, and 22 for each cycle for subjects 75 years and younger.
name
Dexamethasone
other Names
Decadron
type
DRUG

Study design

allocation

RANDOMIZED

intervention Model

PARALLEL

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 12
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Calculate rate of progression-free survival for subjects following treatment BiRd regimen compared to Rd treatment regimen. Progression is determined by the International Myeloma Working Group Criteria.
measure
Survival Duration Without Disease Progression
time Frame
Until disease progression or death from any cause, for a maximum of approximately 5 years

secondary Outcomes

description
Capture the number of subjects who demonstrate a complete or partial response to treatment with BiRD regimen, as compared to Rd. Complete and partial responses are defined by the International Myeloma Working Group Criteria.
measure
Overall Response Rate
time Frame
2 years
description
Capture the number of adverse events experienced with BiRd regimen as compared to Rd regimen
measure
Number of Adverse Events Experienced
time Frame
2 years
description
Survival following treatment to the date of death of subjects on BiRd regimen as compared to Rd.
measure
Overall Survival
time Frame
4 years
description
Progression is determined by the International Myeloma Working Group Criteria.
measure
Number of Days After Initiating Treatment With BiRd Regimen to Disease Progression, as Compared to Subjects on Rd Treatment Regimen.
time Frame
Until disease progression for a maximum of approximately 5 years
measure
Number of Patients With Objective Response Rate (CR+PR)
time Frame
up to 3 years
description
Complete response is defined by the International Myeloma Working Group Criteria.
measure
Number of Patients With Complete Response Rate (CR)
time Frame
up to 3 years
description
Descriptively presented for each treatment group and no formal statistical comparison will be made between treatment arms
measure
Number of Days for Event-Free Survival
time Frame
approximately 5 years
description
Descriptively presented for each treatment group and no formal statistical comparison will be made between treatment arms
measure
Number of Days for Duration of Response
time Frame
up to 3 years
description
Time from study entry until 2nd instance of disease progression. Progression is determined by the International Myeloma Working Group Criteria. Descriptively presented for each treatment group and no formal statistical comparison will be made between treatment arms.
measure
Number of Months to Progression-Free Survival 2
time Frame
approximately 5 years
description
The Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) is a 40-item measure that assesses self-reported fatigue and its impact upon daily activities and function. The FACIT- Fatigue Subscore (FS) is comprised of 13 items, within the total 40-item FACIT-F, that assess fatigue and its impact. This analysis is only based on the FS score. Items are scored on a 5 point Likert-type scale. Item scores can range from 0 ("not at all") to 4 ("very much"), and the total, summed score from 0 to 52; lower scores indicate greater fatigue. The recall period for each item is the past 7 days. Data is descriptively presented for each treatment group and no formal statistical comparison will be made between treatment arms.
measure
Functional Assessment of Chronic Illness Therapy - Fatigue Subscale (FS; Version 4) Score of Patients Receiving BiRd vs Rd Treatment
time Frame
up to 3 years

Full study description

brief Summary: This is a randomized, open-label, phase III study to investigate the efficacy of combination therapy with an induction phase utilizing a combination clarithromycin (Biaxin®), lenalidomide (Revlimid®), dexamethasone (Decadron®), in multiple myeloma patients who are newly diagnosed and require treatment when compared to patients who receive lenalidomide and dexamethasone alone.
detailed Description: This research study is for men and women with newly diagnosed, previously untreated multiple myeloma. The purpose of this study is to observe the how well the different combinations of study drugs work as therapy for patients with newly diagnosed, transplant ineligible, previously untreated multiple myeloma. The study will be done in two arms: BiRd Arm: * Clarithromycin 500mg PO twice daily on days 1-28 for a 28-day cycle * Lenalidomide 25mg PO daily on days 1-21 of a 28-day cycle * Dexamethasone 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle Rd Arm: * Lenalidomide 25mg PO daily on days 1-21 of a 28-day cycle * Dexamethasone 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle Subjects will be treated in 28-day cycles and may continue treatment as long as they are responding to therapy and not experiencing unacceptable side effects or disease progression. There will be an evaluation at the end of each cycle. Participants will be in the study until disease progression or unacceptable toxicity.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-f0a7c1e1baaa905a9944
requested nct id
NCT02516696
primary nct id
NCT02516696
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
b4f07ebe81a63f748ea44a028a2e166280a1470a68f58f3fc189f4f5e4bd03d8
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-f0a7c1e1baaa905a9944
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT02516696
occurrences
context exact
NCT02516696
end
11
exact text
NCT02516696
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/308/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
ca9aaea376139ecd0054f444ad93d99f090cccedbe3a5de88ef52e69cb09a655
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice